BAT CEO Denies Moving Listing to New York

BAT by 2FIRSTS.ai
Mar.18.2024
BAT CEO Denies Moving Listing to New York
British American Tobacco CEO Tadeu Marroco denies plans to move the company's listing from London to New York.

According to a report from the UK's Financial Times, Tadeu Marroco, the CEO of British American Tobacco, has denied the idea of moving the company's listing from London to New York, calling it a "distraction." Previously, the top ten shareholders who were pushing for this change have sold their stakes in the tobacco company.

 

Maroko told the Financial Times that the change of listing venue "will cause a lot of disruption internally," and he is "uncertain if its benefits are as obvious as some people suggest.

 

Last year, Rajiv Jain, Chairman and Chief Investment Officer of the US investment group GQG Partners with $105 billion in assets, urged British American Tobacco to switch its primary listing and clashed with management over the decision to suspend the company's stock buyback program.

 

According to two sources familiar with the matter, GQG sold its 4% stake in British American Tobacco last July because they refused to move and leverage the larger pool of capital in the US, particularly in tobacco stocks. In Europe, an investment environment dominated by ESG considerations means that almost no capital is willing to invest in the tobacco industry.

 

When asked whether he would consider changing the listing location during his tenure, Maroko said, "I believe we should not focus on this issue during this period.

 

He added that there are "many other things" he needs to do, including income in the United States and new products. "There is no indication that... going to the United States is a certainty."

 

He acknowledged that the London capital market is working hard to attract and retain listed companies, but he mentioned the advantages of staying in the UK for investors. Companies that have already moved their main listing venues to the United States include building materials group CRH, packaging company Smurfit Kappa, and gambling group Flutter.

 

Marroco stated, "If you hold shares in a British (listed) company and are overseas, you do not have to pay withholding tax on dividends, unlike in the United States."

 

He said, "I hope that within 10 years, we no longer have to have these discussions." "The reason why there is such a high level of emotions today is due to the frustration caused by some people leaving."

 

For investors, the main reason they are attracted to invest in tobacco stocks is the capital return from dividends and stock buybacks. One of the biggest active investors in British American Tobacco is Spring Mountain Investments, which is an investment vehicle of Kenneth Dart, a billionaire from the Cayman Islands and one of the world's largest foam cup manufacturers.

 

British American Tobacco announced this month that it will use the proceeds from the sale of a portion of its shares in Indian conglomerate ITC for £1.7 billion to restart its stock buyback program, starting with a £700 million buyback this year.

 

Marroco stated, "For me, the most important thing is the restart of repurchases, which should be a consistent feature of our capital allocation."

 

British American Tobacco is facing challenges in reversing the decline in tobacco sales in the United States, its largest market. This is due to people turning to cheaper brands and alternative tobacco products, in which the company is lagging behind the highly successful PMI, whose IQOS heated tobacco product has been very successful.

 

British American Tobacco's goal is to have 50% of its revenue come from alternative products by 2035, such as its Vuse e-cigarette and Glo heated tobacco devices.

 

Marroco acknowledged that English-American Tobacco "started late in the heated tobacco products field," but he stated that due to the company's market share in the US, they have the ability to catch up. "We have a large business in the US that can be used to sell (new products)."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Philip Morris Japan (PMJ) launched Bold Ruby as a new regular color for the IQOS ILUMA i and IQOS ILUMA i ONE in Japan on September 16, 2026, priced at JPY 6,980 and JPY 3,980, respectively. Initial sales began through IQOS online and physical channels, with convenience stores and selected tobacco retailers set to follow from September 29. Bold Ruby is a regular rather than limited-edition colorway and is available for the ILUMA i and ILUMA i ONE, but not the ILUMA i PRIME. The release does not involve changes to the devices' core hardware or functions.
Sep.22
Product | DOJO Launches 0+6ml BLAST7K Fresh in UK in September, Retaining 2+8ml Pod Compatibility Ahead of October Per-Milliliter Vaping Duty
Product | DOJO Launches 0+6ml BLAST7K Fresh in UK in September, Retaining 2+8ml Pod Compatibility Ahead of October Per-Milliliter Vaping Duty
DOJO officially launched the BLAST7K Fresh on September 17, 2026, introducing a UK-market prefilled pod product with 6ml of e-liquid and a manufacturer-rated capacity of up to 7,000 puffs. The device features a 1000mAh rechargeable battery, the INSTA-JUICED structure and COREX BLAST dual-mesh technology, while retaining compatibility with existing BLAST pods. The launch comes less than two weeks before the UK's Vaping Products Duty takes effect on October 1. At the new duty rate, 6ml of vaping liquid would correspond to £1.32 in VPD. DOJO has not stated that the product's 6ml format was designed in response to the new duty.
Sep.20
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08